Setterwalls has assisted CombiGene AB in its licensing agreement with Spark Therapeutics

Setterwalls has, together with the Swiss law firm, Vischer, assisted CombiGene AB (listed on Stockholm Nasdaq First North Growth Market) in entering into an exclusive, global collaboration- and licensing agreement for CombiGene’s CG01 project.

The CG01 project is a gene therapy that aims to treat drug resistant focal epilepsy with Spark Therapeutics, a US-based company within the Roche Group.